LD Pensions
VC Fund
Aalborg, Denmark
LD Pensions is a VC fund in Aalborg focused on Biotechnology and Health Care. The Danish parliament decided to found LD at the end of the 1970s with the object of managing what were known as Denmark's “frozen cost-of-living allowancesâ€. As part of the automatic adjustment of wages to cover the cost of living, these allowances should have been paid to employees to offset inflation. The government decided to pay themas a supplementary lump sum pension upon retirement.LD has not received any contributions since 1980, but its assets have increased to about EUR 8,010m because cumulative returns exceed the payments made by the fund. Since 1980 LD's investments have yielded an average return of 10,8% per annum after tax and costs.In March 2004, the Danish parliament adopted a new act on LD Pensions authorising LD Pensions to manage capital for other pension institutions. Furthermore, the act makes it easier for members aged 60 to withdraw their savings with LD Pensions and will allow members to move their savings to other pension institutions. In the wake of the new act, LD has launched measures to capitalise on its asset management competencies, and efforts are being made to render investments more liquid.LD pays a lump sum when a member reaches retirement age and leaves the workforce permanently (or when a member reaches the age of 60). Since its formation in 1980, LD has paid out the funds in 1.5m accounts, which leaves the number of accounts from which balances have not been distributed at 1m.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries LD Pensions invests in
Stages LD Pensions invests in
Countries LD Pensions invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Harald Børsting
|
|||
Investment Focus
Industry
- Biotechnology 6 (100%)
- Health Care 4 (67%)
- Medical 1 (17%)
- Genetics 1 (17%)
- Hospital 1 (17%)
Stage
- Funding Round 3 (50%)
- Series B 1 (17%)
- Series C 1 (17%)
- Series F 1 (17%)
Country
- Denmark 4 (67%)
- United States 2 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Harald Børsting
Chairman
|
Chairman | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
7TM Pharma
|
7TM Pharma is a biotech company that discovers and develops drugs with a primary therapeutic focus on diabetes, gastrointestinal, metabolic, asthma, and vascular diseases. The company offers seven transmembrane-spanning receptors, including TM38837, a small molecule CB1 receptor antagonist; TM30339, a NPY Y4 selective agonist that is used withingastrointestinal disorders, and short bowel syndrome; and CRTH2 antagonist, an oral drug for inflammatory or respiratory diseases.7TM Pharma was founded in 2000 and is based in Lyngby, Hovedstaden. | $15M / Jan 15, 2009 | |
AdvanDx
|
AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for the identification of pathogens causing critical infections in hospitalized patients. Its mission is to help healthcare providers optimize antibiotic therapy earlier in order to improve patient outcomes while limiting unnecessary antibiotic use and reducing hospitalcosts.AdvanDx was founded in 2002 and headquartered in Woburn, Massachusetts. | $15M / Series C / Sep 18, 2007 | |
Exiqon
|
Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and thedevelopment of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences. | $20M / Jun 03, 2005 | |
NsGene
|
NsGene is a Danish Biotech company located in the Medicon Valley region. The Company is committed to developing novel biological products for the treatment of neurological diseases and is focusing on multiple indications with high unmet needs, including Alzheimer's disease, epilepsy, neuropathic pain and Parkinson's disease. | $5.1M / May 02, 2005 | |
T-cellic
|
T-cellic develops solutions for immunology and tumor biology. | $6.3M / Series B / Nov 07, 2003 | |
Acadia Pharmaceuticals Inc.
|
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: Acadia Pharmaceuticals AB based in Malmo, Sweden and Acadia Pharmaceuticals A/S based in Denmark. TheCompany is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study. | $25M / Series F / Mar 31, 2003 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does LD Pensions invest in?
LD Pensions invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Series B stage. Most of the 6 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact LD Pensions?
Public channels for LD Pensions include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at LD Pensions?
The team at LD Pensions includes Harald Børsting (Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
